TNNI3K and cardiomyopathy: In addition, Tnni3k-correlated genes were also enriched (with a p-value < 0.05) in cardiomyopathy, cardiac muscle contraction, and glucose metabolism pathways (Figure 4B), including “hypertrophic cardiomyopathy” (p = 0.007); “cardiac muscle contraction” (p = 0.014); “dilated cardiomyopathy” (p = 0.023); “glucagon signaling” (p = 0.019); “fructose and mannose metabolism” (p = 0.037); “citrate/TCA cycle” (p = 0.023); “pyruvate metabolism” (p = 0.025); and “insulin signaling” (p = 0.029).